Mucosis BV, a clinical-stage Dutch biotechnology company developing innovative mucosal vaccines, today announced that it has signed a research and license option agreement with Crucell Holland B.V. (Crucell), the Dutch developer of vaccines and antibodies. Crucell is one of the pharmaceutical companies of Johnson & Johnson. In the research collaboration, Crucell will make use of Mucosis's proprietary Mimopath platform technology and know-how in Crucell's programme for developing undisclosed novel vaccines to combat infectious diseases.

Under the terms of the agreement, Mucosis will receive upfront payments and could receive additional payments on the achievement of agreed upon milestones. Financial details of the agreement were not disclosed.

"We are delighted to collaborate with Crucell as we strongly believe that our Mimopath platform combined with Crucell's expertise in vaccine development create a substantial opportunity to develop differentiated and medically relevant vaccine candidates," said Thomas Johnston, CEO of Mucosis. "We are proud of the progress we've made to date in developing the Mimopath platform, including our recent positive human clinical trials. We see this agreement as a further validation of our platform and its potential to combat infectious diseases."